Filing Details
- Accession Number:
- 0001209191-20-010234
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-18 17:00:01
- Reporting Period:
- 2020-02-14
- Accepted Time:
- 2020-02-18 17:00:01
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1653087 | Alector Inc. | ALEC | Biological Products, (No Disgnostic Substances) (2836) | 462702363 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1757964 | Robert Paul | C/O Alector, Inc. 131 Oyster Point Blvd, Suite 600 South San Francisco CA 94080 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-02-14 | 3,000 | $29.07 | 270,719 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-14 | 7,000 | $29.74 | 263,719 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $28.45 to $29.44 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $29.45 to $30.06 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Billionaire Hedge Funds
